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Inhibition of Zika virus replication
by G-quadruplex-binding ligands
Prativa Majee,1 Aryamav Pattnaik,2 Bikash R. Sahoo,2 Uma Shankar,1 Asit K. Pattnaik,2 Amit Kumar,1
and Debasis Nayak1
1Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh 453552, India; 2School of Veterinary Medicine and
Biomedical Sciences and Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
Zika virus (ZIKV), amosquito-transmitted Flavivirus, emerged
in the last decade causing serious diseases and affecting human
health globally. Currently, no licensed vaccines or antivirals are
available to combat ZIKV, although several vaccine candidates
are in the pipeline. In recent years, the presence of non-canon-
ical G-quadruplex (GQ) secondary structures in viral genomes
has ignited significant attention as potential targets for anti-
viral strategy. In this study, we identified several novel
conserved potential GQ structures by analyzing published
ZIKV genome sequences using an in-house algorithm. Bio-
physical and biochemical analysis of the RNA sequences con-
taining these potential GQ sequences suggested the existence
of such structures in the ZIKV genomes. Studies with known
GQ structure-binding and -stabilizing ligands such as Braco-
19 and TMPyP4 provided support for this contention. The
presence of these ligands in cell culture media led to significant
inhibition of infectious ZIKV yield, as well as reduced viral
genome replication and viral protein production. Overall,
our results, for the first time, show that ZIKV replication can
be inhibited by GQ structure-binding and -stabilizing com-
pounds and suggest a new strategy against ZIKV infectionmiti-
gation and control.
INTRODUCTION
The emergence of the Zika virus (ZIKV) is of great concern world-
wide in recent times. Though the virus was first isolated in 1947 in
the Zika forest of Uganda,1 it came to prominence mainly after the
2007 outbreak for its association with serious congenital and neuro-
logical abnormalities.2–5 The outbreaks, which occurred sporadically
in parts of African and Asian countries, later manifested into major
outbreaks in the Island of Yap, Federated States of Micronesia6 in
2007, French Polynesia7 in 2013, and the most explosive outbreak
in Brazil8,9 in 2015. It is estimated that over 86 countries across the
world have now witnessed ZIKV infections. The ZIKV infection
may be asymptomatic or manifest as mild, self-limiting, flu-like
febrile illnesses that are resolved within days. In certain cases, it can
even give rise to congenital abnormalities and severe complications
in children, including microcephaly, hydrocephaly, cerebral atrophy,
ventriculomegaly, cortical malformations, intracranial calcifications,
etc.2–5,10 In adults, ZIKV infection may lead to fatal conditions
involving neurological complications like acute auto-immune-medi-
ated damage to peripheral nerves (Guillain-Barré syndrome), neurop-
athy, myelitis, meningoencephalitis, ischemic infarction, seizures,
vasculopathy, etc.11,12
ZIKV, along with other mosquito-borne viruses like dengue virus
(DENV), West-Nile virus (WNV), and Yellow fever virus (YFV), be-
longs to the Flaviviridae family. This enveloped virion consists of a
positive-sense single-stranded RNA genome that codes for a single
polyprotein that is further processed into three structural (capsid
[C], precursor membrane [prM], and envelope [E] protein) and seven
non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5).13 As there is no effective licensed vaccine or drug currently
available, various strategies and approaches are being explored for the
discovery of antiviral drugs against ZIKV. These include targeting
viral proteins (structural and NS), repurposing the already approved
drugs, etc.,14 and therefore further research on alternate strategies for
the discovery of new and effective antiviral compounds is warranted.
The G-quadruplex (GQ)-forming sequences are being explored
extensively as potential drug targets and have gained significant atten-
tion as potential antiviral strategies in recent years.15,16 The stretches
of guanines in DNA or RNA sequences self-assemble to form a non-
canonical secondary structure that can provide a specialized binding
pocket for planar ligands.17 Targeting GQ structures for cancer treat-
ment are being explored continuously for a very long time as they are
reported to be extensively found in the telomeric region of the human
chromosome.18 They are subsequently present in the promoter region
of several proto-oncogenes like Bcl2 (B cell lymphoma 2)19 and c-Myc
(cancer myelocytomatosis).20 Promisingly, researchers have designed
ligands, which can specifically target these GQ sequences and inhibit
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the growth of cancer cells.21–23 These sequences also play significant
role in neurodegenerative diseases like fragile X syndrome, Amyotro-
phic Lateral Sclerosis, and frontotemporal dementia.24,25 The search
of biologically important GQ sequences has been ramified in other
organisms as well, including yeast,26 bacteria,27–29 parasites,30 and vi-
ruses.15,16 Several viruses including ZIKV,31 human papillomaviruses
(HPV),32 herpes simplex virus (HSV),33 and human immunodefi-
ciency virus (HIV)34 are reported to bear GQ-forming sequences in
their genome. Founded on this, the GQ-binding ligands such as
Braco-19 and core-extended naphthalene diimides are reported to
have a significant antiviral effect on HIV replication.35,36 Another
potent GQ-binding ligand, TMPyP4, was found to stabilize the GQ
structure in the Ebola virus polymerase (L) gene, thereby repressing
its expression at the RNA transcription level.37 A similar effect of
TMPyP4 was also observed in the case of the core gene of hepatitis
C virus (HCV).38 These studies provide a framework for further
research on the potential use of GQ-binding and -stabilizing ligands
for antiviral strategies.15,16
In a recent report, Fleming et al.31 first reported the presence of pu-
tative GQ-forming sequences in the ZIKV genome that are largely
conserved among the Flaviviridae family, although the functional
consequences of the presence of such structures were not examined
by the investigators. In this study, we have discovered a number of
additional GQ-structure-forming sequences that are exclusively
conserved in the ZIKV genome in addition to those reported by
Fleming et al.31 Taking ZIKV genomic RNA sequences carrying
several of these potential GQ structures, and by using various assays
such as fluorescence titration assay, nuclear magnetic resonance
(NMR) spectral analysis, isothermal titration calorimetric (ITC)
assay, and thermal denaturation experiments, we show that (1) the
GQ structures do in fact exist in these RNA sequences, (2) the GQ-
binding ligands such as Braco-19 and TMPyP4 bind specifically to
these structures and stabilize them, and (3) treatment of ZIKV-
infected cells with these ligands results in significant reduction in
infectious virus production, as well as inhibition of viral genome
replication and viral protein production in a dose-dependent manner.
Thus, GQ-ligand binding strategy displayed in this study stands as a
proof of concept and appears promising toward the development of
potential antiviral agents against ZIKV infection.
RESULTS
ZIKV genome has potential GQ structures conserved across the
strains
Earlier reports suggest that Flaviviruses including the ZIKV contain
conserved GQ-forming sequences.31 By employing more stringent
criteria where the number of guanine repeat was kept R2 and the
loop length was restricted between 1 and 7, we identified four new
ZIKV GQs (ZGQs) conserved in the NS genes such as NS2, NS4B,
and NS5 genes of ZIKV genome in addition to the other ZGQs iden-
tified previously (Figure 1A).31 Importantly, the genome-widemining
of 247 ZIKV isolates revealed that these new ZGQs are conserved
among >90% of the ZIKV strains (Figure 1B; Tables S1, S2, and
S9). As Figure 1B displays, the WebLogo representation of the newly
predicted four ZGQ sequences shows that the guanine residues
involved in the GQ formation are highly conserved among the
different evaluated strains and the residues present in the loop region
are mostly divergent. Because ZIKV is an RNA virus, it is prone to a
higher mutation rate,39 and thus, the conservation of these ZGQs
across the isolates suggests functional importance associated with
viral life cycle and pathogenesis. In addition, we have also identified
highly conserved ZGQ sequence motifs in the viral anti-genomic
(negative-sense) RNA (Figure S1; Table S3).
After identifying the ZGQ sequences in the positive-sense genomic
RNA, we conducted circular dichroism (CD) spectroscopy and nu-
clear magnetic resonance (NMR) spectroscopy studies to determine
whether they would form the GQ structures in vitro. It is well docu-
mented that these RNA GQ-forming sequences show less polymor-
phism in topology as compared to the DNA GQs and they are usually
observed to form parallel topology, with one reported exception, i.e.,
Spinach, as it forms the anti-parallel topology.17 Consistent with this
notion, we observed that the newly predicted ZGQs formed the signa-
ture pattern for parallel topology in the CD spectra, i.e., a negative
peak at 240 nm and a positive peak at 265 nm in the presence
of different cations (Figure 2A). Additionally, the 1H NMR spectra
showed distinct chemical shift signals between 10.5 and 12 ppm,
Figure 1. G-quadruplex (GQ) structures are conserved in ZIKV genome
(A) Schematic diagram showing the location of the GQ sequences predicted in the
ZIKV genome. The seven ZGQ sequences used in the study are distributed in the NS
genes, namely, NS2, NS3, NS4B, and NS5, and one in the 30 UTR region. (B)
WebLogo representation of the newly predicted four ZGQ sequences showing
conservation of the nucleotides among different strains. The height of the letter
indicates the relative frequency of the particular nucleotides at that position,
therefore reflecting the conservation of that particular nucleotide.
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which depict the characteristic peaks of the imino region embracing
the Hoogsteen base pairing in the GQ structures (Figure 2B). These
results are consistent with the formation of ZGQ structures within
the ZIKV RNA sequences examined here.
Interaction of potential ZGQs with GQ-binding ligand Braco-19
demonstrated by fluorescence-binding assay
Along with the advent of predicting and analyzing GQ structures, the
development of small-molecule ligands, which could specifically
target these GQ structures, have also been intensified. GQ-specific
molecules like Braco-19 and TMPyP4 are extensively used for target-
ing GQ structures in the telomere region,40–42 in viruses like in HIV35
and HSV.33 These particular molecules are immensely used to distin-
guish and characterize GQ forming sequences from the canonical
DNA or RNA sequences. Thus, we evaluated the interaction ability
of these GQ-specific ligands with the predicted ZGQs. We performed
fluorescence-binding assays of Braco-19 with all the four newly pre-
dicted ZGQs along with the earlier reported GQs (ZNS3, ZNS5A,
ZNS5B, and Z3UTR).31 This assay is a simple optical assay that makes
use of the intrinsic fluorescence property of the ligandmolecule. Fluo-
rescence-binding assay helps to determine the binding affinity be-
tween two molecules (in our case, the GQ-specific ligand, Braco-19,
and the RNA) and obtain a quantitative value in the form of dissoci-
ation constant (KD).
43 The binding efficiency between the ligand and
the biological molecules, i.e., RNA, is evaluated through the difference
Figure 2. Biophysical characterization of ZGQs
(A) CD spectra analysis of ZGQs showing parallel RNA
topology in the presence of cations, namely, K+, Na+, Li+,
and Mg2+. (B) 1H NMR spectra analysis of the ZGQs
showing the signature imino proton peaks in the predicted
four ZGQs, thus confirming the Hoogsteen bond forma-
tion in GQ structure.
between the fluorescence intensity observed
before the addition of the RNA and after its
interaction with the ligand. The successful inter-
action results in either increase (enhancement)
or decrease in fluorescence intensity (quench-
ing). This change in fluorescence (DF) is plotted
with respect to the concentration of RNA (GQs
or canonical) using global curve fitting methods
to obtain the KD values for each interaction. The
respective KD value is used to analyze the bind-
ing affinity of the fluorescent molecule with each
nucleic acid. In the present study, all the ZGQs
showed higher binding affinity (>100-fold
higher) for Braco-19 in comparison to the
duplex control RNA sequence (Figure 3; Table
S4). The variation in binding affinity of different
ZGQs with Braco-19 is probably due to different
polymorphic structures formed by the GQ-se-
quences and so the ligand molecules bind with
the different RNA sequences with varying inten-
sity. It should be noted that a higher affinity of Braco-19 toward the
GQ sequences is attributed by the p-p interactions between the aro-
matic region of the ligand and the GQ-forming scaffolds of the ZGQs.
Moreover, Braco-19 contains two pyrrolidine rings, which contribute
to the cationic nature of the molecule and help to interact with the
anionic core of the GQ structures. All these properties contribute to
the mode of binding between the ligand and the biomolecule and
thereby can exhibit different binding modes, for example, groove
binding or end-stacking modes. In our study, all the sequences
were best fitted in the two-mode binding model depicting more
than one site being present in the RNA sequences for the ligand bind-
ing. The KD1 values were higher in each case, confirming preferential
binding mode and better affinity of the ligand toward the ZGQ
sequences.
The higher binding affinity of Braco-19 with ZGQs confirmed by
ITC
ITC is regarded as the gold standard technique for determining the
thermodynamic properties of a bio-molecular interaction. Unlike
the fluorescence-binding assay, it not only provides the binding con-
stant values but also offers insight into the thermodynamic parame-
ters including enthalpy changes, stoichiometry value, entropy
changes, and Gibbs free energy. Thus, we performed ITC studies us-
ing the ZGQs and Braco-19 to have better insight regarding the inter-
action profile. Interestingly, the binding affinity values between
www.moleculartherapy.org
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Braco-19 and ZGQs were observed in mMscale, while with the control
duplex RNA, the value ranged in mM scale confirming that the GQ
specific ligand, Braco-19 has a higher selectivity for the ZGQ-forming
structures over the non-GQ-forming sequences (Figure 4; Table S5).
ITC was also performed for the ZGQs with TMPyP4 and in similar
manner; TMPyP4 also showed a higher affinity for the GQ sequences
(Figure S2; Table S7). In certain binding thermograms, for example in
Figures 4A–4D, we find endothermic binding where the saturation
level is low, while the reactions turn exothermic at higher levels of
saturation. This implies that the stronger binding of the ligand to
the RNA is entropically driven while those that show weaker binding
are enthalpically directed.44
Thermal denaturation profile shows the stabilization of the
ZGQs by Braco-19
The thermal denaturation experiments illustrate the stability of the
GQ structures. The gradual increase in temperature leads to a change
in conformation of the nucleic acid structure due to disruption of the
bonds between the bases making it less stable.45 The higher melting
temperature (Tm) signifies higher stability of the nucleic acid confor-
mation. In our assays, when the ligand, Braco-19, was added in double
the molar concentration to that of the ZGQ RNA solution, we
observed a significant increase in Tm values. Tm differences of
3.6C to 13.1C were noted for different ZGQs on interaction with
Braco-19 (Figure 5; Table S6). The ligand molecule interacts with
the GQ structures, thereby stabilizing them by forming non-covalent
bonds. On interaction with the ligand molecules, these GQ structures
become relatively more stable at higher temperature, which in turn
increases the melting temperature.
ZIKV growth is inhibited in vitro in the presence of GQ-binding
compounds Braco-19 and TMPyP4
The studies described above suggest that the ZIKV genome contains
GQ structures that can be stabilized through the binding of Braco-19,
as well as TMPyP4. To determine whether the presence of such struc-
tures and stabilizing them through binding with Braco-19 could
impact ZIKV growth in cultured cells, we performed experiments
to assess ZIKV growth in Vero cells in the presence of varying con-
centrations of the drug. Vero cells infected with MR766 isolate of
ZIKV were treated with Braco-19 and infectious virus yield in the su-
pernatants at various time points was measured by plaque assay. In
response to Braco-19 treatment, starting from 48 h post-infection,
the total infectious virus yield showed a significant reduction in a
dose-dependent manner, at each of the time points examined (Fig-
ure 6A). Strikingly, at 100 mM of Braco-19 (cell viability was greater
than 85% (Figure 6C) at 100 mM concentration), inhibition of virus
growth was most significant (>80-fold, p % 0.0001) at 96 hpi
compared to the untreated control (Figure 6A). We also investigated
the effect of TMPyP4, another GQ-binding molecule on virus yield in
a similar assay. Our results showed that TMPyP4 also inhibited virus
growth significantly (Figure 6B). At a concentration of 10 mM, at
which cell viability was over 80% (Figure 6C), the infectious virus
yield in the supernatants at 72 hpi and 96 hpi was reduced nearly
120-fold and 170-fold, respectively, compared to the untreated con-
trol (Figure 6B). However, at 100 mM concentration, the infectious vi-
rus yield in the supernatant was below the limit of detection at any of
the time points studied (Figure 6B), even though the cell viability was
nearly 40% (Figure 6C). Overall, these results suggest that GQ-bind-
ing compounds Braco-19 and TMPyP4 inhibit ZIKV growth in vitro.
To determine whether the lower levels of infectious virus in the cul-
ture supernatants in the presence of the Braco-19 or TMPyP4 were
a result of increased accumulation of cell-associated infectious virus,
we quantitated the amount of virus present in the cells. As can be seen
in Figure 6D, on average, cell-associated virus represented about
17-fold less than the virus released in the supernatants of infected cells
under no-drug treatment condition at 72 hpi. In the presence of
100 mM Braco-19 or 10 mM TMPyP4, cell-associated virus repre-
sented approximately 14- to 15-fold less than that in the correspond-
ing supernatants. Importantly, the cell-associated virus in drug-
treated cells were significantly lower than those in untreated cells
(Figure 6D). These results show that both Braco-19 and TMPyP4
inhibit infectious ZIKV progeny production.
Inhibition of viral protein synthesis and genome replication in
infected cells treated with Braco-19 and TMPyP4
Since Braco-19 and TMPyP4 treatment reduced infectious ZIKV
yield, we next sought to find out whether this is due to lower viral pro-
tein expression in infected cells. We examined the E protein expres-
sion levels in virus-infected cells in the presence of Braco-19 or
TMPyP4. Since the ZIKV genome is translated into a single large pol-
yprotein, which is processed to yield 10 different proteins including
the E protein, we picked the E protein as an indicator viral protein
production. Vero cells, infected with MR766 ZIKV, were treated
with varying concentrations of Braco-19 or TMPyP4 immediately af-
ter infection. Cell lysates were prepared from the infected cells at 48 or
96 hpi and analyzed for E protein levels by western blot, which
showed a marked reduction in E protein expression with increasing
concentrations of Braco-19 at both 48 hpi and 96 hpi (Figures 7A
and 7B). The reduction of E protein levels was more pronounced at
100 mM Braco-19 and at 96 hpi. In response to TMPyP4 treatment,
E protein expression showed observable reduction over time (Fig-
ure 7C). Surprisingly, the electrophoretic mobility of the E protein
Figure 3. Fluorescence titration studies of Braco-19 with different ZGQ
RNAs
The solid, colored lines represent the plot for fitting the data obtained due to the
interactions of Braco-19 with the respective RNAs by two-mode binding. Table S4
lists the binding constant values (KD) obtained after fitting the plots.
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was demonstrably altered at 48 hpi time point (Figure 7C), with
increasing dose of TMPyP4 resulting in increased molecular mass
of the E protein. Interestingly at 96 hpi, the reduced electrophoretic
mobility of E was only observed with 100 mM TMPyP4 (lane 5, Fig-
ure 7D) and was also less pronounced. The reason for the observed
electrophoretic mobility shift in E protein in the presence of TMPyP4
is unclear at this time but it is possible that metabolic byproducts of
TMPyP4, known to be generated in cells could bind to the E protein in
a time- and concentration-dependent manner to reduce the mobility
of the E protein (see Discussion for further details). Nevertheless, our
results suggest that both Braco-19 and TMPyP4 inhibit viral protein
expression in infected cells.
We next sought to determine whether intracellular replication of the
ZIKV genome is negatively affected by the GQ-binding ligands. Vero
cells, infected with ZIKV MR766, were treated with Braco-19,
TMPyP4, or left untreated and total RNA from the cells was extracted
at 72 and 96 hpi. Total RNA was subjected to qRT-PCR with
Figure 4. Braco-19 has a higher binding affinity and
thermal profile for ZGQs
Isothermal titration calorimetric experiment showing the
binding affinity between the ZGQ RNAs and Braco-19
(A: ZGQ1, B: ZGQ2, C: ZGQ3, D: ZGQ4, E: ZNS3, F:
ZNS5A, G: ZNS5B, H: Z3UTR and I: Duplex RNA-Con-
trol). The top panel represents the power in mcal unit
versus time in s while the bottom panel depicts the
thermogram of the integrated peak intensities plotted
against the molar ratio. The binding constant values for all
the ZGQ RNAs along with the control RNA are listed in
Table S5.
ZIKV-specific primers and probes to determine
the copy numbers of the viral positive-sense
genome. In these experiments, we used
100 mMBraco-19 because this concentration ex-
hibited maximum inhibition without adversely
affecting cell viability and 10 mM TMPyP4
because higher concentration of TMPyP4 was
found to reduce cell viability substantially (Fig-
ure 6C). Results from the experiment showed
that ZIKV genome copies were significantly
lower in cells treated with Braco-19 or TMPyP4
at both 72 and 96 hpi (Figure 7E), suggesting
that these GQ-binding molecules inhibit ZIKV
genome replication in infected cells. Overall,
from these studies we conclude that GQ-binding
drugs inhibit both viral genome replication, as
well as translation.
DISCUSSION
Due to the unavailability of commercial vaccines
or antiviral drugs, control and mitigation strate-
gies for ZIKV infection remain a huge challenge
to date. The unpredictable nature of ZIKV out-
breaks and the global prevalence of its vector have further worsened
the situation. Although attempts to repurpose the drugs like Sofosbu-
vir,46 Niclosamide,47 and Galidesivir48 have shown pronounced anti-
Zika activity, these drugs also come with certain shortcomings such as
poor bioavailability, poor liberation, and improper mode of adminis-
tration. If infected during pregnancy, ZIKV can cause detrimental ef-
fects on the fetus and eventually on the newborn. Prognosis of
newborn babies infected with ZIKV is unfavorable and infections
could lead to permanent congenital defects. Thus, utmost precaution
and precision should be taken while strategizing therapeutic counter-
measures against ZIKV infection.
In recent years, GQ structures, which are non-canonical nucleic acid
secondary structures, are being discovered in almost all organisms
including many viral genomes and thus have been considered as
potential targets for antiviral strategies.16 ZIKV and other Flaviviruses
are earlier reported to possess conserved GQ structures.31 By expand-
ing the analysis to all the available ZIKV genome sequences published
www.moleculartherapy.org
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in theNCBIGenomedatabase and employing an in-house algorithm,49
we were able to predict four additional highly conserved GQ structures
inZIKV. SomeGQ-forming sequenceswere also found to be conserved
in the anti-genomic strand of the ZIKV (replication intermediate; Fig-
ure S1; Table S3). However, further studies will be required to validate
whether they actually form GQs. The current study mainly focuses on
theGQstructures formed in the genomicRNA (positivepolarity) of the
ZIKV. The observation that these GQ structures are highly conserved
suggested to us that they may play a specific role in the biology and/or
pathogenesis of the virus. Two of the GQs were found to be located in
the coding region ofNS5 gene, i.e., the RNA-dependent RNApolymer-
ase coding gene, while the other twowere present in theNS2 andNS4B
gene. These GQs were characterized by CD and NMR spectra analysis
and were found to form parallel GQ structures. Moreover, it has been
previously shown thatRNAGQstructures aremore stable compared to
their DNA counterparts due to the presence of the 20 hydroxyl group in
the ribose sugar. Following CD andNMR spectra studies, we evaluated
whether these GQ structures would interact with the knownGQ-bind-
ing ligands. GQ-binding ligands such as Braco-19, TMPyP4, etc. have
been widely studied to measure the stability of the GQ structures and
are presently being explored as an antiviral strategy. The ligands bear
certain characteristics like basic aromatic rings, electron-deficient
cationic core, and positively charged side chains, which facilitate the
efficient interaction of these ligands with the GQ secondary struc-
tures.50 The mode of interaction of these ligands may be through
end-stacking, groove binding, or interaction with the backbone or
loop sequences. The molecules fit themselves within these GQ struc-
tures and bind through various non-covalent bonds thus stabilizing
the structure. Further biophysical studies including the fluorescence
titration assay, ITC, and thermal denaturation assay conclusively
demonstrated that theBraco-19 andTMPyP4bind selectively andpref-
erentially to the GQ-forming sequences in comparison to the non-GQ
linear RNA sequences.Our studies unequivocally demonstrated the ex-
istence and formation of GQ structures in the genome of ZIKV.
We reasoned that the binding of the Braco-19 orTMPyP4 could poten-
tially impact the function(s) of the viral RNA containing the GQ struc-
tures. Our in vitro studies in cells infected with ZIKV and treated with
Braco-19 or TMPyP4 suggested that both of these compounds inhibit
the activities of the RNA template. Viral protein synthesis was substan-
tially reduced in a dose-dependentmanner as evidenced by the reduced
levels of the E protein in the cells compared to control cells. Addition-
ally, it is possible that binding of these compounds to theGQ structures
inhibited the movement of the viral RNA polymerase, resulting in
Figure 5. Thermal denaturation analysis showing stabilization ZGQs in the presence of Braco-19
The increase in Tm depicts the stable interaction of the ZGQs with Braco-19 (A: ZGQ1, B: ZGQ2, C: ZGQ3, D: ZGQ4, E: ZNS3, F: ZNS5A, G: ZNS5B and H: Z3UTR). The Tm
difference (noted in the left bottom corner) is significant for all the ZGQ RNAs (also see Table S6).
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overall reduction of viral RNA copy numbers as we have observed in
our experiments. Although our studies revealed the existence of multi-
ple functionalGQstructures in the viral genome, itwouldbe interesting
to examine whether a particular GQ structure functions more promi-
nently than the other structures. In this regard, further studies are being
planned to identify a specific contribution of these GQ structures in in-
hibiting viral genome replication and translation.
Examination of E protein in ZIKV-infected cells treated with
TMPyP4 revealed slower migrating forms of the protein (Figures
7C and 7D). It appears to be specific for E protein since such mobility
differences were not observed with another viral protein, the NS1 pro-
tein (data not shown). The molecular basis for the differences in
mobility of E compared to that in TMPyP4-untreated cells is not clear
at this time. However, it is known that TMPyP4 becomes metabo-
lized51 in cells through oxidation by hemeoxygenase enzymes
(HO-1 and HO-2) to produce 4-formyl-1-methylpyridinium (4F-
MP) and 4-carboxyl-1-methylpyridinium (4C-MP). Since these
metabolites can bind to certain cellular proteins such as acetylcholin-
esterase,51 it is possible that 4F-MP and/or 4C-MP bind specifically to
the viral E protein in a time- and concentration-dependent manner to
reduce its mobility. Although our results are consistent with such an
interpretation, further research is needed to determine the molecular
basis of the observed mobility shift in the E protein.
Taken together, our studies provide the first evidence that highly
conserved GQ structures present in ZIKV genome and the ligands
that bind and stabilize these GQ structures can potently inhibit
ZIKV growth, genome replication, and viral protein expression in
cultured cells. However, the two ligands evaluated here are the
most common GQ-specific ligands used regularly to characterize
these secondary structures and not highly specific to the particular
ZIKV GQs. Moreover, the toxicity and bioavailability of these ligands
pose a hindrance for their potential use as antiviral drugs. Though this
piece of research stands as a proof of concept for using GQ-binding
ligands as anti-ZIKV drugs, development of sequence-specific ligands
needs further research.16 Moreover, the availability of ligands that can
potentially target ZIKV GQ sequences and that have the ability to
distinguish them from the host GQs can address the problem of
off-target effects of the ligands. Thus, these results open the possibility
for understanding the role of GQ structures in ZIKV life cycle and
pathogenesis, as well as for use of these structures as targets for devel-
opment of innovative and efficacious antiviral strategies.
MATERIALS AND METHODS
Oligonucleotides and reagents
Small-molecule ligands, namely Braco-19 and TMPyP4, were pur-
chased from Sigma Aldrich Chemicals, dissolved in water or DMSO,
respectively, for preparation of stock solutions, and stored at 4C until
further use. Other reagents and chemicals including KCl, KH2PO4,
K2HPO4, DMSO, and D2O were procured from Sigma Aldrich Chem-
icals or HiMedia Laboratories. The DNA oligonucleotides and the
RNA oligonucleotides used in the studies were obtained from Sigma
Aldrich Chemicals and IDT Technologies, respectively (Table S8).
Figure 6. Inhibition of ZIKV growth in cells treated
with Braco-19 and TMPyP4
(A and B) Vero cells infected with ZIKV at an MOI of 1 were
incubated in medium containing 0 (untreated), 1 mM,
10 mM, and 100 mM concentrations of Braco-19 (A) or
TMPyP4 (B). Aliquots of culture supernatants were
collected at various times (h post-infection, hpi) and in-
fectious virus titers were determined by plaque assay. The
graphs show mean values of virus titers, with error bars
representing standard deviations from the results of four
independent experiments. Two-way ANOVA was used to
determine significant differences in virus titers between
untreated and drug-treated samples. LOD, the limit of
detection. # represent values below LOD. ****p% 0.0001;
***p % 0.001; ns, nonsignificant. (C) Cell viability in the
presence of Braco-19 or TMPyP4. Vero cells were
exposed to 0, 1, 10, and 100 mMBraco-19 or TMPyP4 for
4 days and percentage of viable of cells was measured.
Mean values from three independent experiments with
error bars representing standard deviations are shown. (D)
Vero cells were infected with ZIKV at an MOI of 1 and
treated with 100 mM Braco-19 or 10 mM TMPyP4 for
72 hpi. Infectious virus in the supernatants and cells were
quantitated by plaque assay. The graphs show mean
values of virus titers, with error bars representing standard
deviations from the results of three independent experi-
ments. Two-way ANOVA was used to determine signifi-
cant differences in virus titers between untreated and
drug-treated samples. ***p % 0.001; **p % 0.01.
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Prediction of putative GQ-forming sequences from the ZIKV
genome
A total of 247 complete genome sequences of ZIKV were retrieved
from the NCBI Genome database (https://www.ncbi.nlm.nih.gov/
genomes). The FASTA sequences of the ZIKV genomes were then
used for the prediction of the putative GQ-forming sequences with
the help of our in-house GQ prediction tool.48 The search was based
on the following algorithm:
GR2N17GR2N17GR2N17GR2
where G corresponds to guanine and N corresponds to any base
including guanine. Though the ZIKV is a positive-sense RNA virus,
we also sought to find the probable GQ sequences in the anti-sense
strand of the viral genome. Further, the consensus sequences for
each of the ZGQs studied were generated using the WebLogo
software.52
CD melting analysis
J-815 spectropolarimeter (JASCO) attached with a Peltier junction
temperature controller was used to perform the CD experiment.
With continuous supply of nitrogen gas, the required temperature
was maintained to avoid condensation of water along the cuvette.
20 mM RNA sample dissolved in Tris buffer (10 mM, pH = 7.4, sup-
plemented with the required cation) was used for the CD spectra anal-
ysis. For the CD spectra analysis, the wavelength range of 220–320 nm
was scanned at the speed of 20 nm/min while the thermal denatur-
ation experiments were carried out at 265 nm at a temperature
range of 25C to 98C. The ligand was added gradually in increasing
concentration to the ZGQ RNA solution. The experiments were done
in triplicate and data were obtained and normalized by buffer subtrac-
tion. Following this, the result was plotted using SigmaPlot 12.0 soft-
ware (Systat Software, Chicago, IL, USA).
NMR spectroscopy
The NMR experiment was carried on in the AVANCE 400 MHz
(BioSpin International AG, Switzerland) spectrometer supported
with the 5 mm broadband inverse (BBI) probe as reported earlier.28
Fluorescence-binding assay
The fluorescence titration experiment was performed using the Syn-
ergy H1multi-mode plate reader. 2 nM of ligand was added to each of
the 12 wells of a 96-well plate and gradually the target RNA was
titrated in each of the wells (0–10 mM). Precisely, the highest concen-
tration of RNA, i.e., 10 mM, was added to first well, followed by dilu-
tion in the subsequent well; for example, the second well then
contained 5 mM, third well contained 2.5 mM, and so on until the elev-
enth well while no RNA was added in the last well (twelfth well)
serving as blank. The enhancement in emission fluorescence was
observed at specific excitation of the ligand molecule (lex = 360 nm
and lem = 440 nm for Braco-19) on addition of RNA and the change
in emission fluorescence (DF) for all datasets was normalized to the
last well (containing no RNA). The two-site saturation using global
curve fitting was used to extrapolate the curve between DF and
concentration of RNA (mM) using SigmaPlot 12.5 software (Systat
Software, Chicago, IL, USA) according to the following equation
that accounts for two receptor binding sites with two different affin-
ities, KD1 and KD2:
y =
Bmax1  abs xð Þ
KD1  abs xð Þ +
Bmax1  abs xð Þ
KD2  abs xð Þ
where Bmax is the maximum number of binding sites and KD is the
dissociation equilibrium constant. Each binding study was performed
in duplicate at room temperature (RT) and duplex RNA was used as
the control.
ITC experiment
The ITC experiments were performed using the MicroCal iTC200
isothermal titration calorimeter (GE Healthcare) instrument. The
RNA sample was prepared in potassium phosphate buffer and loaded
in the cell while the ligand was loaded in the syringe. A total of 21
Figure 7. Braco-19 and TMPyP4 inhibit viral protein synthesis and genome
replication
(A–D) Vero cells were either mock-infected (M) or infected with ZIKV at an MOI of 1
and subsequently incubated in medium containing 0, 1 mM, 10 mM, and 100 mM
concentrations of Braco-19 (A and B) or TMPyP4 (C and D). Cell extracts were
prepared at 48 hpi (A and C) or 96 hpi (B and D) and 20 mg of proteins from each
sample were analyzed by SDS-PAGE and western blotting with 4G2 antibody to
detect viral E protein. Levels of actin detected in the blots using anti-actin antibody
served as the loading control. Molecular mass markers (in kDa) are shown on the
left. Representative data are shown in each panel. (E) Levels of viral genome in the
presence of Braco-19 or TMPyP4. Vero cells infected as above were and incubated
in medium without drug (untreated) or containing 100 mM Braco-19 or 10 mM
TMPyP4. Viral genome copies in the cells at 72 and 96 hpi were quantitated and
expressed as copies per mg of total cellular RNA from the cells. The graphs show
mean values of genome copy numbers with error bars representing standard de-
viations from the results of three independent experiments. Two-way ANOVA was
used to determine significant differences between untreated and drug-treated
samples. ****p % 0.0001; ***p % 0.001.
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injections were performed where each injection delivered 1.78 mL of
ligand and was of 3.56 s duration with a gap of 120 s between two.
An initial injection of 0.4 mL having 60 s initial equilibrium delays
wasmaintained during each experiment. Throughout the experimental
period, 25C temperature and 750 rpm speed were sustained. The data
obtained were fitted to the two-site binding model and analyzed using
the Origin scientific software version 7 (Microcal Software).
Cells and viruses
Vero (Cercopithecus aethiops, CCL-81) cells were obtained from
American Type Culture Collection (ATCC). The cells were grown
and maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% heat-inactivated fetal bovine serum (FBS) and peni-
cillin/streptomycin (PS) in humidified chamber with 5% CO2 at
37C. The infectious clone-derived MR766 strain of ZIKV53 gener-
ated in our laboratory was used in this study. For determination of vi-
rus growth in the presence of Braco-19 or TMPyP4, Vero cells were
infected with the virus at a multiplicity of infection (MOI) of 1 pla-
que-forming unit per cell (PFU/cell). Following adsorption at 37C
for 1 h, the inoculum was removed and replaced with virus growth
medium as described before53,54 containing appropriate concentra-
tions of Braco-19 or TMPyP4. Infected cells were incubated at 37C
and small aliquots of infected cell culture supernatants were collected
at various hpi, clarified, and stored at 80C for virus titration at a
later time. To determine the amount of cell-associated infectious vi-
rus, after collecting culture supernatants, we subjected the cells to
two cycles of freeze-thaw at 80C in the presence of the same vol-
ume of growth medium followed by centrifugation at 17,000  g
for 10 min at 4C. The clarified supernatants were then used to quan-
tify the cell-associated virus. Virus quantitation was performed by
plaque assay on Vero cells as described previously.53
Western blotting for E protein
ZIKV E protein was detected in infected cells treated without or with
the GQ-binding ligands at appropriate concentrations. Cell extracts
were prepared, and the viral E protein was detected by western blot-
ting as described before.53 Anti-ZIKV E protein antibody was ob-
tained from Genetex (Cat. # GTX1333325) and goat anti-rabbit
immunoglobulin G (IgG)-horseradish peroxidase (HRP)-conjugated
(Cat. # A6154) was procured from Sigma Aldrich. Mock-infected or
virus-infected cells were washed with cold PBS, trypsinized, and har-
vested at 500  g for 5 min at 4C. The cell pellet was resuspended in
radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl,
pH 7.6, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS) supplemented with the protease and phosphatase inhibitor
cocktail and incubated on ice for 15 min with intermittent vortexing
after which the lysates were clarified by centrifugation at 10,000  g
for 5 min, 4C. Total protein quantification was done using the bicin-
choninic acid (BCA) assay kit. 20 mg of total protein was separated by
electrophoresis on a required percentage of polyacrylamide gel
(PAGE) containing sodium dodecyl sulfate (SDS). The separated
proteins were transferred onto polyvinylidene fluoride (PVDF) mem-
branes using a Bio-Rad semi-dry transfer system. Non-specific pro-
tein binding was blocked with 5% non-fat milk or with bovine serum
albumin (for phosphorylated proteins) in Tris-buffered saline con-
taining 0.2% Tween 20 (TBS-T) and incubated with the appropriate
primary antibodies (dilution: 1:5,000 for b-actin and 1:1,000 for all
others) at 4C overnight. Membranes were washed with TBS-T and
incubated with appropriate HRP-conjugated secondary antibodies
(dilution: 1:5,000) at RT for 2 h. Bands were detected using enhanced
chemiluminescence (ECL) western blotting substrate using a BioRad
imager.
Quantitative real-time PCR
Total RNA from infected cells at 72 or 96 hpi were isolated using TRI-
zol RNA isolation reagent (Thermo Fisher Scientific) and viral
genomic copy numbers were determined using specific probes and
primers as described in detail previously53 and expressed as log10
copies per mg of total cellular RNA. The forward primer (50-GTC
GTTGCCCAACACAAG-30) and the reverse primer (50-CCAC
TAATGTTCTTTTGCAGAC-30) along with the fluorescent probe
50-/56-FAM (50-6-carboxyfluorescein)/AGCCTACCT/ZEN/TGACA
AGCAATCAGACACTCAA/3IABkFQ (30-Iowa black fluorescent
quencher)/-30 were used to determine the standard curve. The real-
time PCR assays involved two steps. The first step included the
cDNA synthesis from the viral RNA using the SuperScript II (Thermo
Fisher Scientific, Waltham, MA, USA). The synthesized cDNAs were
then used as templates in the qPCR. The qPCR cycling conditions
used were as follows: initial denaturation at 95C for 10 mins; 35 cy-
cles of 95C for 30 s, 55.3C for 30 s, and 72C for 30 s; and a melt
curve from 65C to 95C with 0.5C increments for 5 s. The reactions
were run in CFX Connect instrument (Bio-Rad, Hercules, CA, USA).
Viral-genome copy numbers were determined in parallel reactions
using RNA samples in duplicate and expressed as copy numbers
per mg of total cellular RNA.
Determination of cell viability by flow cytometry
Cell viability was determined by simultaneous determination of pro-
pidium iodide (PI, 1 mg/mL, Sigma Aldrich, P4170) uptake as a
marker of plasmamembrane integrity loss and changes in the forward
scatter properties of the cell (cell size) using flow cytometry (fluores-
cence-activated cell sorting [FACS]). Flow cytometry and data anal-
ysis were performed as described previously.55
Statistical analysis
Data were analyzed using GraphPad Prism software version 6.0. Two-
way ANOVA was used to determine significant differences between
untreated and drug-treated samples for viral loads (RNA copies, in-
fectious titer). Data were represented as either mean ± SEM or
mean ± SD.
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Table S1: The details of GQ sequences used in the study which includes their cG score and 
cC score and their corresponding gene location. The GQ sequences shown here were 
predicted using the in-house prediction tool1 where cG score and cC score help to reduce the 
false positive prediction and a higher cG/cC score depicts that the sequence has greater 















































































Table S2: The details of GQ sequences used in the study predicted using an online available 
GQ prediction tool named QGRS mapper.3 The G-score assigned by the tool helps to 
understand the plausibility of the sequences to form a stable GQ structure. Higher the G-score, 





Position Length QGRS Mapper 
G-
Score 
1 ZGQ1 4210 20 GGAGUGGGAAGCGGAGCUGG 36 
2 ZGQ2 7474 24 GGACCGCCUGGGGGUGGGGGGAGG 33 
3 ZGQ3 8168 13 GGUGGGGGAUUGG 34 
4 ZGQ4 8269 18 GGUAUGGGGGAGGACUGG 35 
5 ZNS3 5043 31 GGAAGAGUGAUAGGACUCUAUGGCAAUGGGG 32 
6 ZNS5A 7668 14 GGGGGUGGAACAGG 33 
7 ZNS5B 7908 21 GGAUGUGGCAGAGGGGGCUGG 35 
8 Z3UTR 10778 16 GGCGGCCGGUGUGGGG 32 
 
Table S3: The details of GQ sequences predicted in the anti-sense strand (-ve) of the Zika 
genome using the in-house prediction tool.1 The table includes the cG score and cC score of GQ 














1 AS-ZGQ1 GGUGGCGGCAGGG 90 20 NS5 gene 98.8 
2 AS-ZGQ2 GGCUAUGAGGCCAUCUUGGAGG 90 40 NS3 gene 98.8 
3 AS-ZGQ3 GGGUUCCUGGUGGCGUGG 100 30 NS3 gene 96.8 
4 AS-ZGQ4 GGUCUCUAGGGUCUCCGGCAAUUGGG 100 60 NS4A gene 95.9 
5 AS-ZGQ5 GGAUGGUGGCGG 80 10 NS5 gene 93.1 
6 AS-ZGQ6 GGGGGGAGUCAGGAUGG 110 10 NS1 gene 91.9 
 
Table S4: Table displays the binding constant values of the Zika GQs with Braco-19 obtained 
through the Fluorescence titration assay along with the control RNA. 
 ZGQ1 ZGQ2 ZGQ3 ZGQ4 ZNS3 ZNS5A ZNS5B Z3UTR 
Duplex 
RNA 
Kd1 0.090μM 0.708μM 0.017μM 0.035μM 0.0388µM 0.0227μM 0.0512μM 0.0225μM 13.053µM 
Kd2 4.852μM 13.337μM 0.323μM 2.907μM 9.035μM 2.640μM 4.386μM 0.533μM 13.060μM 
3 
 
Table S5: Table displays the binding constant values of the Zika GQs with Braco-19 obtained 
through the Isothermal Titration Calorimetric assay along with the control RNA. 
 ZGQ1 ZGQ2 ZGQ3 ZGQ4 ZNS3 ZNS5A ZNS5B Z3UTR 
Duplex 
RNA 
Kd1 0.758μM 0.091μM 1.946μM 0.870μM 1.629µM 0.018μM 0.247μM 0.054μM 621.118µM 
Kd2 0.758μM 0.649μM 0.312μM 0.008μM 46.083μM 41.322μM 54.054μM 23.809μM 6.451μM 
 
Table S6:  Table displaying the ΔTm values of Zika GQs binding with Braco-19 molecule 
evaluated by the CD thermal denaturation experiment. 
 ZGQ1 ZGQ2 ZGQ3 ZGQ4 ZNS3 ZNS5A ZNS5B Z3UTR 
ΔTm 11.5°C 7.1°C 5.6°C 8.6°C 7.4°C 13.1°C 3.6°C 11.3°C 
 
Table S7: The table encloses the binding constant values for all the ZGQ RNAs along with the 
control RNA with TMPyP4 obtained through Isothermal titration calorimetric experiment. 
 ZGQ1 ZGQ2 ZGQ3 ZGQ4 ZNS3 ZNS5A ZNS5B Z3UTR 
Kd1 0.231μM 0.020μM 15.038μM 2.762μM 17.7µM 0.110μM 99.010μM 3.610μM 
Kd2 0.376μM 1.475μM 369.004μM 163.399μM 15.083μM 19.455μM 124.844μM 602.41μM 
 





1 ZPQ1 AAGGAGUGGGAAGCGGAGCUGGC 
2 ZPQ2 CUGGGGGUGGGGGGAGGCUGGGGC 
3 ZPQ3 AGUGGUGGGGGAUUGGCUA 
4 ZPQ4 GAGGUAUGGGGGAGGACUGGU 
5 ZNS3 GGUGGAAGAGUGAUAGGACUCUAUGGCAAUGGGGUU 
6 ZNS5A GUGGAGGUGGGACGGGAG 
7 ZNS5B UCGGAUGUGGCAGAGGGGGCUGGAG 





Figure S1: G-quadruplex structures are conserved in anti-sense strand of the ZIKV 
genome. WebLogo representation of the predicted G-quadruplex sequences showing 
conservation of the nucleotides among different strains. Larger size letter denotes the maximum 
conservation of the nucleotide while the smaller, the size of the letter represent lesser degree of 





Figure S2: Isothermal titration calorimetric experiment showing the binding affinity between the 
ZGQ RNAs and TMPyP4. The top panel represents the power in μcal unit versus time in seconds 
while the bottom panel depicts the thermogram of the integrated peak intensities plotted against 
the molar ratio.  
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